Диссертация (1140223), страница 30
Текст из файла (страница 30)
2010; 11(9):660–669.169. Thamer C., Machann J., Haap M., Bachmann O., Wietek B., Dahl D. et al. Reducedinsulin effect in subclinical fatty liver // Dtsch Med Wochenschr. 2004; 129:872-875.170. Thamer C., Machann J., Tschritter O., Haap M., Wietek B., Dahl D. et al.Relationship between serum adiponectin concentration and intramyocellular lipid storesin humans // Horm Metab Res. 2002; 34.171.
The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial(ASCOT) Investigators. Differential Impact of Blood Pressure–Lowering Drugs onCentral Aortic Pressure and Clinical Outcomes. Principal Results of the Conduit ArteryFunction Evaluation (CAFE) Study // Circulation. 2006; 113:1213-25.172.
Tilg H., Diehl A., Li Z., Lin H., Yang S. Cytokines and the pathogenesis ofnonalcoholic steatohepatitis // Gut. 2005; 54:303–306.173. Trayhurn P. Adipocyte biology // Obesity Reviews. 2007; 8(1):41-44.174. Unger R.H., Orci L. Lipotoxic diseases of nonadipose tissues in obesity // Int J ObesRelat Metab Disord.
2000; 24(4):28-32.175. Van Gaal L.F., Mertens I.L., De Block C.E. Mechanisms linking obesity withcardiovascular disease // Nature. 2006; 444:875–80.176. Varani J., Dame M.K., Taylor C.G., Sarma V., Merino R., Kunkel R.G. et al. Agedependent injury in human umbilical vein endothelial cells: relationship to apoptosis andcorrelation with a lack of A20 expression // Lab Invest. 1995; 73(6):851-858.177.
Vasan R.S. Cardiac function and obesity // Heart. 2003; 89:1127-1129.178. Vasan R.S., Beiser A., Seshadri S., Larson M.G., Kannel W.B., D Agostino R.B.,Levy D. Residual lifetime risk for developing hypertension in middle-aged women andmen. The Framingham Heart Study // JAMA. 2002; 287:1003-1010.179. Vempati U.D., Diaz F., Barrientos A., Narisawa S, Mian AM, Millan JL, et al. Roleof Cytochrome c in Apoptosis: Increased Sensitivity to Tumor Necrosis Factor Alpha IsAssociated with Respiratory Defects but Not with Lack of Cytochrome c Release //Molecular and Cellular Biology. 2007; 27(5):1771-1783.170180. Verdecchia P., Angeli F., Borgioni C., Gattobigio R., de Simone G., Devereux R.B.et al. Changes in cardiovascular risk by reduction of left ventricular mass inhypertension: a meta-analysis // Amer J Hypertension.
2003; 16:11.181. Wallace A.M., McMahon A.D., Packard C.J., Kelly A., Shepherd J., Gaw A. et al.Plasma leptin and the risk of cardiovascular disease in the West Of Scotland CoronaryPrevention Study (WOSCOPS) // Circulation. 2001; 104:3052–3056.182. Wang J., Wang H., Luo W., Guo C., Chen Y.E., Chang L. et al. Leptin-inducedendothelial dysfunction is mediated by sympathetic nervous system activity // J. Am.Heart. Assoc. 2013; 2(5):000299.183. Weigert J., Neumeier M., Wanninger J., Bauer S., Farkas S., Scherer M.N.
et al.Serum Galectin-3 Is Elevated in Obesity and Negatively Correlates with GlycosylatedHemoglobin in Type 2 Diabetes // J Clin Endocrinol Metab. 2010; 95:1404-1411.184. WHO. Obesity: Preventing and Managing the Global Epidemic. World HealthOrganisation: 2000. (www.who.int), Fact sheet N°311, 2015.185. Wiest R., Groszmann R.J.
The paradox of nitric oxide in cirrhosis and portalhypertension: too much, not enough // Hepatology. 2002; 35:478–491186. Wolk R., Berger P., Lennon R.J., Brilakis E.S., Johnson B.D., Somers V.K. et al.Plasma leptin and prognosis in patients with established coronary atherosclerosis // J AmColl Cardiol. 2004; 44(9):1819-1824.187. Xu C., Lee S., Singh T.M., Sho E, Li X, Sho M. et al. Molecular mechanisms ofaortic wall remodeling in response to hypertension // J Vasc Surg. 2001; 33:570-578.188.
Xu F.P., Chen M.S., Wang Y.Z., Yi Q, Lin S.B., Chen A.F. et al. Leptin induceshypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal ratcardiomyocytes // Circulation. 2004; 110:1269–1275.189. Yamagishi S., Imaizumi T. Diabetic vascular complications:pathophysiology,biochemical basis and potential therapeutic strategy // Curr Pharm Des. 2005;11(18):2279–2299.190. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E Jr, Drazner M.H. et al.ACCF/AHA guideline for the management of heart failure: a report of the AmericanCollege of Cardiology Foundation/American Heart Association Task Force on PracticeGuidelines // J Am Coll Cardiol.
2013; 62(16):147–239.171191. Yilmaz H., Cakmak M., Inan O., Darcin T., Akcay A. et al. Increased levels ofgalectin-3 were associated with prediabetes and diabetes: new risk factor? // Journal ofEndocrinological Investigation. 2014; 38(5):1-7.192. Younossi Z.M., Stepanova M., Afendy M., Fang Y., Younossi Y., Mir H., SrishordM. Changes in the prevalence of the most common causes of chronic liver diseases in theUnited States from 1988 to 2008 // Clin Gastroenterol Hepatol. 2011; 9:524-530.193. Yousef Z.R., Redwood S.R., Marber M.S. Post-infarction left ventricularremodelling: a pathophysiological and therapeutic review // Cardiovascular Drugs andTherapy. 2000; 14:243–252.194. Zibadi S. Metabolic syndrome-induced cardiac fibrosis // The University ofArizona.
2009; 129 pages..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
